Eledon Pharmaceuticals, Inc.
ELDN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001404281
No open-market purchases or sales by Eledon Pharmaceuticals, Inc. insiders were filed in the last 90 days; 154 institutions reported holding it in 13F filings for Q3 2026, worth $115.1M in total; no superinvestor holds it.
Holders of 5% or more of ELDN
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Eledon Pharmaceuticals, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Biotechnology Value Fund L P | 13G/A | 9.99%8.66M shares | 0.00 ppfrom 9.99% | Feb 16, 20219 filings | Nov 16, 2026 | SEC |
| BlackRock, Inc. | 13G | 5.80%4.38M shares | +1.20 ppfrom 4.60% | Jul 17, 20253 filings | Apr 27, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
39 Schedule 13D and 13G filings on Eledon Pharmaceuticals, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Nov 16, 20264:10 PM ET | Biotechnology Value Fund L Pand 9 others | 13G/A | 9.99%8.66M shares | 0.00 ppfrom 9.99% | Sep 30, 2026 | SEC |
| Oct 30, 202611:25 AM ET | Vanguard Capital Management LLC | 13G/A | 4.87%3.96M shares | −0.18 ppfrom 5.05%Below 5% | Sep 30, 2026 | SEC |
| Jul 31, 202610:17 AM ET | Vanguard Capital Management LLC | 13G | 5.05%3.90M shares | New | Jun 30, 2026 | SEC |
| May 15, 20264:07 PM ET | Biotechnology Value Fund L Pand 9 others | 13G/A | 9.99%7.87M shares | – | Mar 31, 2026 | SEC |
| Apr 27, 20264:12 PM ET | BlackRock, Inc. | 13G | 5.80%4.38M shares | +1.20 ppfrom 4.60% | Mar 31, 2026 | SEC |
| Mar 26, 20266:03 PM ET | Vanguard Group Inc | 13G/A | 0.00%0 shares | −5.54 ppfrom 5.54%Below 5% | Mar 13, 2026 | SEC |
| Feb 17, 20264:27 PM ET | Ra Capital Management, L.P.and 3 others | 13G/A | 0.00%0 shares | –Below 5% | Dec 31, 2025 | SEC |
| Feb 13, 20264:15 PM ET | Coastlands Capital LPand 4 others | 13G/A | 4.99%3.94M shares | −0.99 ppfrom 5.98%Below 5% | Dec 31, 2025 | SEC |
| Jan 21, 202612:30 PM ET | BlackRock, Inc. | 13G/A | 4.60%3.63M shares | −0.80 ppfrom 5.40%Below 5% | Dec 31, 2025 | SEC |
| Nov 24, 20253:28 PM ET | Coastlands Capital LPand 4 others | 13G | 5.98%4.76M shares | New | Nov 19, 2025 | SEC |
| Jul 29, 20251:13 PM ET | Vanguard Group Inc | 13G | 5.54%3.32M shares | New | Jun 30, 2025 | SEC |
| Jul 17, 20257:54 PM ET | BlackRock, Inc. | 13G | 5.40%3.25M shares | New | Jun 30, 2025 | SEC |
| Feb 14, 20255:34 PM ET | Armistice Capital, LLCand 1 other | 13G/A | 4.99%3.14M shares | –Below 5% | Dec 31, 2024 | SEC |
| Feb 14, 202511:22 AM ET | Frazier Life Sciences Public Fund, L.P.and 16 others | 13G/A | 2.00%1.18M shares | –Below 5% | Dec 31, 2024 | SEC |
| Nov 14, 2024 | Armistice Capital, LLC | 13G/AOld format | – | – | – | SEC |
| Nov 5, 2024 | Frazier Life Sciences Public Fund, L.P. | 13GOld format | – | New | – | SEC |
| Nov 5, 2024 | Ra Capital Management, L.P. | 13GOld format | – | New | – | SEC |
| Oct 31, 2024 | Biotechnology Value Fund L P | 13G/AOld format | – | – | – | SEC |
| Oct 31, 2024 | Biotechnology Value Fund L P | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2024 | Armistice Capital, LLC | 13GOld format | – | New | – | SEC |
| Feb 14, 2024 | Cormorant Asset Management, LP | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2024 | Biotechnology Value Fund L P | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2023 | Cormorant Asset Management, LP | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2022 | Cormorant Asset Management, LP | 13G/AOld format | – | – | – | SEC |
| Feb 11, 2022 | Woodline Partners LP | 13G/AOld format | – | – | – | SEC |
| Feb 10, 2022 | Adage Capital Partners GP, L.L.C. | 13G/AOld format | – | – | – | SEC |
| Feb 9, 2022 | FMR LLC | 13G/AOld format | – | – | – | SEC |
| Jan 28, 2022 | Biotechnology Value Fund L P | 13G/AOld format | – | – | – | SEC |
| Jan 26, 2022 | Logos Global Management LP | 13G/AOld format | – | – | – | SEC |
| Jan 11, 2022 | Biotechnology Value Fund L P | 13G/AOld format | – | – | – | SEC |
| Jan 11, 2022 | Biotechnology Value Fund L P | 13G/AOld format | – | – | – | SEC |
| Sep 9, 2021 | Logos Global Management LP | 13G/AOld format | – | – | – | SEC |
| Feb 16, 2021 | Woodline Partners LP | 13GOld format | – | New | – | SEC |
| Feb 16, 2021 | 683 Capital Management, LLC | 13G/AOld format | – | – | – | SEC |
| Feb 16, 2021 | Biotechnology Value Fund L P | 13G/AOld format | – | – | – | SEC |
| Feb 8, 2021 | FMR LLC | 13GOld format | – | New | – | SEC |
| Jan 5, 2021 | OrbiMed Israel BioFund GP Limited Partnership | 13D/AOld format | – | – | – | SEC |
| Jan 4, 2021 | Cormorant Asset Management, LP | 13GOld format | – | New | – | SEC |
| Jan 4, 2021 | Adage Capital Partners GP, L.L.C. | 13GOld format | – | New | – | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Eledon Pharmaceuticals, Inc. shares.
No Form 144 notices for Eledon Pharmaceuticals, Inc. are on file.